NEW YORK (GenomeWeb News) – AstraZeneca has selected BioWisdom to provide customized vocabulary and meta-data from its toxicological reports based on its development compounds, BioWisdom said today.
Under the agreement, BioWisdom will convert documents to machine-readable formats, and provide entity extraction and derivation, semantic normalization, mapping, and meta-data.
BioWisdom Chief Scientific Officer Julie Barnes said in a statement that the project "will enable AstraZeneca to harness value from both public and now private repositories of safety-related information."
Financial terms of the agreement were not released.